

Anti-CD20 Antibody (Divozilimab)

Introduction

Divozilimab (BCD-132) is a humanized monoclonal antibody against CD20 (CD20). Divozilimab is used in multiple sclerosis research.

Product parameters

Alternative Names	BCD 132, BCD-132
Target Accession	P11836
Target	CD20
CAS number	2254061-60-2
Molecular Weight	145.26 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized Human CD20 VLP at 5 ug/mL (30 ul/well) can bind Anti-CD20 Antibody (Divozilimab), The EC50 was approximately 0.01698 ug/ml.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

